ArticleBMC gastroenterology2026
Association of bilirubin reduction rate after percutaneous transhepatic cholangiographic drainage with major complications in hilar cholangiocarcinoma.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study evaluated whether the dynamic change in total bilirubin (TBIL) after percutaneous transhepatic cholangiographic drainage (PTCD) was associated with major postoperative complications and 90-day mortality in patients with hilar cholangiocarcinoma (HCCA).
methodsWe retrospectively analyzed 173 patients with HCCA who underwent PTCD before curative-intent resection at three Chinese centers. The bilirubin reduction rate (BRR) was defined as the difference between the TBIL level measured one day before PTCD and that measured one day before surgery, divided by the interval between measurements. Logistic regression was used for major complications, and Firth's penalized logistic regression was used for 90-day postoperative mortality. Receiver operating characteristic analysis assessed the discriminatory performance of BRR for major complications.
resultsMajor complications occurred in 64 patients (37.0%), and 8 patients (4.6%) died within 90 days after surgery. On multivariable analysis, BRR (OR = 0.86, 95% CI 0.79-0.95, p = 0.002) and intraoperative transfusion (OR = 2.04, 95% CI 1.06-3.92, p = 0.033) were independently associated with major complications. Lower platelet count (OR = 0.99, 95% CI 0.97-1.00, p = 0.013) and lower albumin (OR = 0.80, 95% CI 0.65-0.99, p = 0.042) remained independently associated with 90-day postoperative mortality. BRR showed modest discriminatory ability for major complications (AUC = 0.644, 95% CI 0.563-0.726). Using the optimal cutoff value (4.863 μmol/L·day
conclusionsBRR after PTCD was independently associated with major complications after HCCA resection, but its modest discriminatory performance supports its use only as an adjunctive marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.